Skip to main content
SpringerLink
Log in

Activity of gefitinib in advanced non-small-cell lung cancer with very poor performance status

  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Abstract

Advanced non-small-cell lung cancer (NSCLC) patients with poor performance status (PS) are less likely to respond to chemotherapy, or to have an improvement in survival, but more likely to experience toxicity. We retrospectively evaluated the efficacy and tolerability of gefitinib in patients with advanced NSCLC and very poor PS in Taiwan. Patients with stage IIIB, IV NSCLC with an Eastern Cooperative Oncology Group (ECOG) PS of 3–4 received oral gefitinib 250 mg once daily. Totally, 52 patients were included (25 men, 27 women). Forty-three patients (82.7%) were in a PS of 3. Tumor response rate was 25.0% (13/52). Tumor response rate to gefitinib was highest in chemonaive patients 38.1% (8/21) vs. failed 1 chemotherapy regimen 13.3% (2/15) vs. failed 2 or more chemotherapy regimens 18.8% (3/16), p = 0.015. The median overall survival was 2.5 months (response group 9.1 months, stable disease 3.1 months, and progressive group 0.8 month, p < 0.001). Adverse events, mainly skin reactions and diarrhea, were generally mild (grade 1 or 2) except paronychia and acne. Thus, gefitinib has clinically antitumor activity and good tolerability in {Taiwan} patients with advanced NSCLC and very poor performance status, with a higher response rate than that seen Europe or in European heritage Americans. Chemonaive patients responded better than patients with prior chemotherapy. Formal clinical trials are warranted to evaluate the role of gefitinib in this situation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346: 92-98, 2002

    Google Scholar 

  2. Fossella FV, Lee JS, Hong WK: Management strategies for recurrent non-small cell lung cancer. Semin Oncol 24: 455-462, 1997

    Google Scholar 

  3. Ruckdeschel JC, Finkelstein DM, Ettinger DS, Creech RH, Mason BA, Joss RA, Vogl S: A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer. J Clin Oncol 4: 14-22, 1986

    Google Scholar 

  4. Fontanini G, Vignati S, Bigini D, Mussi A, Lucchi H, Angeletti CA, Pingitore R, Pepe S, Basolo F, Bevilacqua G: Epidermal growth factor receptor (EGFr) expression in non-small cell lung carcino-mas correlates with metastatic involvement of hilar and mediastinal lymph nodes in the squamous subtype. Eur J Cancer 31A: 178-183, 1995

    Google Scholar 

  5. Mukaida H, Toi M, Hirai T, Yamashita Y, Toge T: Clinical significance of the expression of epidermal growth factor and its receptor in esophageal cancer. Cancer 68: 142-148, 1991

    Google Scholar 

  6. Neal DE, Marsh C, Bennett MK, Abel PD, Hall RR, Sainsbury JR, Harris AL: Epidermal-growth-factor receptors in human bladder cancer: Comparison of invasive and superficial tumours. Lancet 1: 366-368, 1985

    Google Scholar 

  7. Sainsbury JR, Farndon JR, Needham GK, Malcolm AJ, Harris AL: Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer. Lancet 1: 1398-1402, 1987

    Google Scholar 

  8. Woodburn JR: The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 82: 241-250, 1999

    Google Scholar 

  9. Kris MG, Natale RB, Herbst RS, Lynch TJ, Jr., Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis H, Sandler A, Albain KS, Cella D, Wolf MK, Averbuch SD, Ochs JJ, Kay AC: Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial. Jama 290: 2149-2158, 2003

    Google Scholar 

  10. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, Nishiwaki Y, Vansteenkiste J, Kudoh S, Rischin D, Eek R, Horai T, Noda K, Takata I, Smit E, Averbuch S, Macleod A, Feyereislova A, Dong RP, Baselga J: Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 21: 2237-2246, 2003

    Google Scholar 

  11. Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 47: 207-214, 1981

    Google Scholar 

  12. Jiroutek M, Johnson D, Blum R, Bonomi P, Chang A, Ettinger D, Ruckdeschel J, Schiller J, Sandler A: Prognostic factors in advanced non-small cell lung cancer (NSCLC): Analysis of eastern cooperative oncology group (ECOG) trials from 1981-1992. Proc Am Soc Clin Oncol, 1998 (Abstract #1774)

  13. Argiris A, Mittal N, Masters G: Gefitinib (ZD1839) as first-line, compassionate use therapy in patients with advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol, 2003 (Abstract #2729)

  14. Kommareddy A, Coplin M, Behnken D, Romvari E, Trinkaus K, Read W, Govindan R: Gefitinib as a first line therapy for patients with advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol, 2003 (Abstract #2834)

  15. Wong N, Lim TS, Lim WT, Leong SS, Tan EH: ZD1839 is more effective in patients (pts) with non-small cell lung cancer (NSCLC) who were lifetime non-tobacco users. Proc Am Soc Clin Oncol, 2003 (Abstract #2790)

  16. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139, 2004

    Google Scholar 

  17. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M: EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304: 1497-1500, 2004.

    Google Scholar 

  18. Cohen MH, Williams GA, Sridhara R, Chen G, Pazdur R: FDAdrug approval summary: Gefitinib (ZD1839) (Iressa) tablets. Oncologist 8: 303-306, 2003

    Google Scholar 

  19. Fossella FV, DeVore R, Kerr RN, Crawford J, Natale RR, Dunphy F, Kalman L, Miller V, Lee JS, Moore M, Gandara D, Karp D, Vokes E, Kris M, Kim Y, Gamza F, Hammershaimb L: Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 18: 2354-2362, 2000

    Google Scholar 

  20. Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M, Levitan N, Gressot L, Vincent M, Burkes R, Coughlin S, Kim Y, Berille J: Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18: 2095-2103, 2000

    Google Scholar 

  21. Chang GC, Yang TY, Wang NS, Huang CM, Chiang CD: Successful treatment of multifocal bronchioloalveolar cell carcinoma with ZD1839 (Iressa) in two patients. J Formos Med Assoc 102: 407-411, 2003

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Chest Medicine, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan; Institute of Toxicology, Chung Shan Medical University, Taichung, Taiwan

    Gee-Chen Chang, Kun-Chieh Chen, Tsung-Ying Yang, Ming-Chang Yin, Ching-Pei Lin & Jeng-Yuan Hsu

  2. Department of Medical Research and Education, Taipei Veterans General Hospital, Taiwan

    Benjamin Ing-Tiau Kuo

Authors
  1. Gee-Chen Chang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kun-Chieh Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tsung-Ying Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ming-Chang Yin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ching-Pei Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Benjamin Ing-Tiau Kuo
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jeng-Yuan Hsu
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chang, GC., Chen, KC., Yang, TY. et al. Activity of gefitinib in advanced non-small-cell lung cancer with very poor performance status. Invest New Drugs 23, 73–77 (2005). https://doi.org/10.1023/B:DRUG.0000047108.39129.7c

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/B:DRUG.0000047108.39129.7c

Search

Navigation